Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Jahr

2016

Autoren

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Ziemssen T, Compston DA; CARE-MS II Investigators.

Verlag

Neurology. 2016 Nov 8;87(19):1985-1992.

Link

https://doi.org/10.1212%2FWNL.0000000000003319

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network

COVID-19 and multiple sclerosis: challenges and lessons for patient care

A future of AI-driven personalized care for people with multiple sclerosis

Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons